NVGH Vi-CRM197
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Typhoid Fever
Conditions
Typhoid Fever
Trial Timeline
Oct 1, 2011 → Dec 1, 2011
NCT ID
NCT01438996About NVGH Vi-CRM197
NVGH Vi-CRM197 is a phase 2 stage product being developed by Novartis for Typhoid Fever. The current trial status is completed. This product is registered under clinical trial identifier NCT01438996. Target conditions include Typhoid Fever.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01438996 | Phase 2 | Completed |
Competing Products
7 competing products in Typhoid Fever
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Purified Vi capsular polysaccharide of Salmonella typhi conjugated to tetanus toxoid as carrier protein (Typhoid Vi Conjugate Vaccine I.P.). Trade name: ZyVac® TCV | Zydus Lifesciences | Phase 3 | 77 |
| Vi-CRM197 vaccine + Vi Polysaccharide (PS) vaccine + Pneumococcal conjugate vaccine | Novartis | Phase 2 | 52 |
| NVGH Vi-CRM197 12.5 mcg + NVGH Vi-CRM197 5.0 mcg + NVGH Vi-CRM197 1.25 mcg + Vi-polysaccharide vaccine | Novartis | Phase 2 | 52 |
| Typherix + NVGH Vi-CRM197 | Novartis | Phase 1 | 33 |
| Vi-CRM197 vaccine + Pneumococcal conjugate vaccine + Vi Polysaccharide (PS) vaccine | Novartis | Phase 2 | 52 |
| Vivotif | Bavarian Nordic | Pre-clinical | 20 |
| Dose of 5.0 x 10^9 CFU (Cohort 1) + Dose of 7.5 x 10^9 CFU (Cohort 2) + Dose of 1.1 x 10^10 CFU (Cohort 3) + Dose of of 1.7 x 10^10 CFU (Cohort 4) | Emergent BioSolutions | Phase 2 | 44 |